Hypo- and Hyperphosphatemia at Admission as Independent Factors of Mortality of COVID-19 Patients: Findings from a Retrospective Cohort Study.

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM

International Journal of Endocrinology and Metabolism Pub Date : 2022-07-12 eCollection Date: 2022-07-01 DOI:10.5812/ijem-126386

Marzieh Hadavi, Fakhredin Taghinezhad, Elham Shafiei, Sharif Hama Babakr, Saiyad Bastaminejad, Mohammadreza Kaffashian, Iraj Ahmadi, Aliashraf Mozafari

{"title":"Hypo- and Hyperphosphatemia at Admission as Independent Factors of Mortality of COVID-19 Patients: Findings from a Retrospective Cohort Study.","authors":"Marzieh Hadavi, Fakhredin Taghinezhad, Elham Shafiei, Sharif Hama Babakr, Saiyad Bastaminejad, Mohammadreza Kaffashian, Iraj Ahmadi, Aliashraf Mozafari","doi":"10.5812/ijem-126386","DOIUrl":null,"url":null,"abstract":"Background: Electrolyte imbalances are common in COVID-19 infection and are associated with poor outcomes in hospitalized patients.Objectives: This study examined whether serum phosphate imbalances at admission are associated with mortality in hospitalized COVID-19 patients.Methods: In this registry-based single-center retrospective cohort study, 1349 inpatients with COVID-19 were included from March 2020 to March 2021 in an academic hospital in Ilam (southwest Iran). The Cox proportional hazard (PH) regression model was applied to the data set of COVID-19.Results: The in-hospital median survival time for patients with low, normal, and high serum phosphate levels was 14, 25, and 8 days, respectively. In a multivariate model, adjusted for the other variables, patients with hypophosphatemia (adjusted hazard ratio [HR], 2.53; 95% CI, 1.15 - 5.58; P = 0.02) and hyperphosphatemia (adjusted HR, 1.77; 95% CI, 1.00 - 3.14; P = 0.05) had an increased mortality hazard compared with those who had normal levels of serum phosphate.Conclusions: Our results demonstrate associations of hypophosphatemia and hyperphosphatemia with increased in-hospital mortality in COVID-19 patients. Intensive medical care and more attention must be paid to COVID-19 patients with serum phosphate imbalances at admission.","PeriodicalId":13969,"journal":{"name":"International Journal of Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/2f/ijem-20-3-126386.PMC9661755.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijem-126386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Electrolyte imbalances are common in COVID-19 infection and are associated with poor outcomes in hospitalized patients.

Objectives: This study examined whether serum phosphate imbalances at admission are associated with mortality in hospitalized COVID-19 patients.

Methods: In this registry-based single-center retrospective cohort study, 1349 inpatients with COVID-19 were included from March 2020 to March 2021 in an academic hospital in Ilam (southwest Iran). The Cox proportional hazard (PH) regression model was applied to the data set of COVID-19.

Results: The in-hospital median survival time for patients with low, normal, and high serum phosphate levels was 14, 25, and 8 days, respectively. In a multivariate model, adjusted for the other variables, patients with hypophosphatemia (adjusted hazard ratio [HR], 2.53; 95% CI, 1.15 - 5.58; P = 0.02) and hyperphosphatemia (adjusted HR, 1.77; 95% CI, 1.00 - 3.14; P = 0.05) had an increased mortality hazard compared with those who had normal levels of serum phosphate.

Conclusions: Our results demonstrate associations of hypophosphatemia and hyperphosphatemia with increased in-hospital mortality in COVID-19 patients. Intensive medical care and more attention must be paid to COVID-19 patients with serum phosphate imbalances at admission.

Abstract Image

查看原文本刊更多论文

入院时低磷血症和高磷血症是COVID-19患者死亡的独立因素:一项回顾性队列研究的结果

背景:电解质失衡在COVID-19感染中很常见，并与住院患者预后不良相关。目的:本研究探讨入院时血清磷酸盐失衡是否与住院COVID-19患者的死亡率相关。方法:在这项基于登记的单中心回顾性队列研究中，纳入了2020年3月至2021年3月在伊朗西南部Ilam的一家学术医院住院的1349例COVID-19患者。将Cox比例风险(PH)回归模型应用于COVID-19数据集。结果:低、正常和高血清磷酸盐水平患者的住院中位生存时间分别为14、25和8天。在多变量模型中，校正其他变量后，低磷血症患者(校正危险比[HR]， 2.53;95% ci, 1.15 - 5.58;P = 0.02)和高磷血症(校正HR, 1.77;95% ci, 1.00 - 3.14;P = 0.05)与血清磷酸盐水平正常的患者相比，死亡风险增加。结论:我们的研究结果表明，低磷血症和高磷血症与COVID-19患者住院死亡率增加有关。对入院时出现血清磷酸盐失衡的COVID-19患者，应给予重症监护和更多关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrinology and Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

3.10

自引率

4.80%

发文量

期刊介绍： The aim of the International Journal of Endocrinology and Metabolism (IJEM) is to increase knowledge, stimulate research in the field of endocrinology, and promote better management of patients with endocrinological disorders. To achieve this goal, the journal publishes original research papers on human, animal and cell culture studies relevant to endocrinology.